# OnCo record pi-rads (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/pi-rads/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "pi-rads" ;
  schema:name "PI-RADS (Prostate Imaging Reporting and Data System)"@en ;
  schema:alternateName "PI-RADS"@en, "PIRADS"@en, "PI-RADS v2.1"@en, "PI-RADS score"@en, "PI-RADS 3"@en, "PI-RADS 4"@en, "PI-RADS 5"@en, "Prostate Imaging Reporting and Data System"@en ;
  schema:description "The international scoring system radiologists use to say how likely a prostate MRI finding is to be a serious cancer, from 1 (very unlikely) to 5 (very likely). British NHS reports usually do not use it: NICE asks for a 5-point Likert score instead, and the two look identical on the page and are not the same thing."@en ;
  schema:url <https://onco.cc/terms/pi-rads/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/PI-RADS> ;
  schema:citation <https://doi.org/10.1016/j.eururo.2019.02.033>, <https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Reporting-and-Data-Systems/PI-RADS>, <https://www.nice.org.uk/guidance/ng131/chapter/Recommendations>, <https://doi.org/10.1016/s0140-6736(16)32401-1>, <https://doi.org/10.1016/j.eururo.2018.11.031> ;
  onco:tag "gu", "prostate-glossary" ;
  onco:related <https://onco.cc/key-papers/paper-ahmed-promis-multiparametric-mri-lancet-2017/>, <https://onco.cc/key-papers/paper-precision-mri-targeted-biopsy-nejm-2018/>, <https://onco.cc/terms/whole-mount-pathology/>, <https://onco.cc/terms/template-mapping-biopsy/>, <https://onco.cc/technologies/prostate-screening-psa-mri/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-low-risk/>, <https://onco.cc/cancers/prostate-intermediate-risk/>, <https://onco.cc/cancers/prostate-high-risk/> ;
  onco:sections <https://onco.cc/fronts/imaging/>, <https://onco.cc/fronts/diagnostics/>, <https://onco.cc/fronts/early-detection/> ;
  onco:technologies <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/prostate-screening-psa-mri/>, <https://onco.cc/technologies/active-surveillance/> ;
  onco:terms <https://onco.cc/terms/psa-density/>, <https://onco.cc/terms/gleason-grade-group/>, <https://onco.cc/terms/whole-mount-pathology/>, <https://onco.cc/terms/template-mapping-biopsy/>, <https://onco.cc/terms/screening/>, <https://onco.cc/terms/psa/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-early-detection/>, <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-overdiagnosis/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ahmed-promis-multiparametric-mri-lancet-2017/>, <https://onco.cc/key-papers/paper-precision-mri-targeted-biopsy-nejm-2018/>, <https://onco.cc/key-papers/paper-johnson-mpmri-individual-foci-eur-urol-2019/> .